arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Aptose Biosciences Inc.

APTOF

— Price unavailable

11 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Excellent

Bullish

auto_awesome

Analytical Summary

Aptose Biosciences Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC —

FCF / Share $-8.99 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close.

11-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-25.47M

— -0.1% —

FCF / Share Free cash flow per share

$-8.99

↑ +82.5% —

trending_up

Bullish Indicators

Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Returns

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 40-F ↗	FY 2015 Jan 1, 2016 40-F ↗
EPS Growth YoY (%)	71.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	84.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-3244.6% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-831.5% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-0.1% Weak ↓ Weak Declining Year-over-year change in net income	50.3% Excellent ↑ Excellent Improving Year-over-year change in net income	-22.4% Weak ↑ Weak Improving Year-over-year change in net income	36.0% Excellent ↑ Excellent Improving Year-over-year change in net income	-18.3% Weak ↑ Weak Improving Year-over-year change in net income	-110.2% Weak ↓ Weak Declining Year-over-year change in net income	9.0% Fair ↑ Fair Improving Year-over-year change in net income	-147.9% Weak ↓ Weak Declining Year-over-year change in net income	18.2% Good Good Year-over-year change in net income	-21.6% Weak Weak Year-over-year change in net income	—
FCF Growth YoY (%)	82.5% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	74.0% Excellent Excellent Year-over-year change in free cash flow	-3668.5% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 40-F ↗	FY 2015 Jan 1, 2016 40-F ↗
FCF / Net Income (x)	0.86x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.41x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.67x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.61x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 40-F ↗	FY 2015 Jan 1, 2016 40-F ↗
Return on Common Equity (%) (%)	93.7% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+525%)	—	—	-110.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-839%)	-88.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-687%)	-46.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-410%)	-28.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-287%)	-205.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1467%)	-114.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-861%)	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 40-F ↗	FY 2015 Jan 1, 2016 40-F ↗
Net Debt (USD)	$-935.00K	$-6.15M	$-9.25M	$-36.97M	$-39.11M	$-117.39M	$-79.84M	$-15.30M	$-10.63M	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 40-F ↗	FY 2015 Jan 1, 2016 40-F ↗
Revenue per Share (USD)	$0.00	$0.00	$0.00	$0.00	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-10.41	$-36.38	$-227.43	$-6.80	$-0.73	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-8.99	$-51.48	$-198.17	$-5.26	—	—	—	—	—	—	—
Book Value per Share (USD)	$-10.64	$-2.26	$-10.96	$6.13	$0.81	$1.34	$1.23	$0.37	$0.37	—	—
Tangible Book Value per Share (USD)	$-10.64	$-2.26	$-10.96	$6.13	$0.81	$1.34	$1.23	$0.37	$0.37	—	—
Basic Weighted Avg Shares (shares)	2.45M	698,980	225,154	6.15M	89,086	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 40-F ↗	FY 2015 Jan 1, 2016 40-F ↗
Working Capital (USD)	$-2.86M	$5.07M	$-3.38M	$37.23M	$73.56M	$118.26M	$93.23M	$13.70M	$10.06M	—	—
Total Equity (USD)	$-27.17M	$-4.54M	$-2.90M	$37.74M	$74.24M	$118.92M	$93.93M	$14.08M	$10.20M	—	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 40-F ↗	FY 2015 Jan 1, 2016 40-F ↗
Sales/Revenue/Turnover (USD)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	—	—	—	—	—
Depreciation Expense (USD)	$22.00K	$32.00K	$88.00K	$120.00K	$150.00K	$152.00K	$152.00K	$87.00K	$84.00K	—	—
Net Income, GAAP (USD)	$-25.47M	$-25.43M	$-51.21M	$-41.82M	$-65.35M	$-55.24M	$-26.28M	$-28.87M	$-11.64M	$-14.24M	$-11.71M
Operating Cash Flow (USD)	$-21.99M	$-35.98M	$-44.59M	$-32.32M	$-43.30M	$-33.89M	$-21.56M	$-23.21M	$-10.22M	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 11 years · 36 quarters

Aptose Biosciences Inc.

Analytical Summary

11-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare APTOF with peers